Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453255 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5742885 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL2054368 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5742883 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL29550748 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5940491 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5940482 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL29550782 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL26547622 | 0.93 | MEN1 (0.42) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL25706923 | 0.92 | MEN1 (0.38) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240246934-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2024-07-25 | — | — | US | disclosed |
| EP-4293016-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | Beijing Scitech-MQ Pharmaceuticals Limited (CN) | 2023-12-20 | — | — | EP | disclosed |
| WO-2023128350-A1 | HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER COMPRISING SAME AS ACTIVE INGREDIENT | 주식회사 비투에스바이오 | 2023-07-06 | — | — | WO | disclosed |
| CN-116157388-A | Carbocyclic amide derivative and application thereof in medicine | 四川海思科制药有限公司 | 2023-05-23 | — | — | CN | disclosed |
| WO-2022253101-A1 | PYRIDAZINONE COMPOUND AS PARP7 INHIBITOR | 上海优理惠生医药有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022194265-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | 北京赛特明强医药科技有限公司 | 2022-09-22 | — | — | WO | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
| WO-2022053000-A1 | CARBOCYCLIC AMIDE DERIVATIVE AND APPLICATION THEREOF IN MEDICINE | 四川海思科制药有限公司 | 2022-03-17 | — | — | WO | disclosed |
| EP-3447051-B1 | METHOD FOR PREPARING TYROSINE KINASE INHIBITOR AND DERIVATIVE THEREOF | JIANGSU HENGRUI MEDICINE CO (CN) | 2021-12-15 | — | — | EP | disclosed |
| EP-3699177-A1 | PREPARATION METHOD FOR TYROSINE KINASE INHIBITOR AND INTERMEDIATE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2020-08-26 | — | — | EP | disclosed |
| US-20200239443-A1 | Preparation Method for Tyrosine Kinase Inhibitor and Intermediate Thereof | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-21 | — | — | US | disclosed |
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-10-17 | — | — | US | disclosed |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190127350-A1 | METHOD FOR PREPARING TYROSINE KINASE INHIBITOR AND DERIVATIVE THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-02 | — | — | US | disclosed |
| WO-2019076316-A1 | PREPARATION METHOD FOR TYROSINE KINASE INHIBITOR AND INTERMEDIATE THEREOF | 江苏恒瑞医药股份有限公司 | 2019-04-25 | — | — | WO | disclosed |
| WO-2019027960-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | WO | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315724-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | MEN1 3327/4885KMT2A 2047/4885ALDH1A1 3753/4885 |
| US-20240246934-A1 | QUINAZOLINE-BASED COMPOUND, COMPOSITION, AND APPLICATION OF QUINAZOLINE-BASED COMPOUND | ABL1, ERBB2, EGFR | MEN1 2736/4885KMT2A 1090/4885ALDH1A1 4496/4885 |
| US-20200239443-A1 | Preparation Method for Tyrosine Kinase Inhibitor and Intermediate Thereof | ABL1, ABL2, LYN | MEN1 1443/4885KMT2A 543/4885ALDH1A1 3329/4885 |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | MEN1 3327/4885KMT2A 2047/4885ALDH1A1 3753/4885 |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | MEN1 3327/4885KMT2A 2047/4885ALDH1A1 3753/4885 |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | MEN1 3327/4885KMT2A 2047/4885ALDH1A1 3753/4885 |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | MEN1 3327/4885KMT2A 2047/4885ALDH1A1 3753/4885 |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | MEN1 3327/4885KMT2A 2047/4885ALDH1A1 3753/4885 |
| US-20190127350-A1 | METHOD FOR PREPARING TYROSINE KINASE INHIBITOR AND DERIVATIVE THEREOF | ABL1, LCK, FYN | MEN1 1466/4885KMT2A 618/4885ALDH1A1 2764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.